Sign in
CompletedPhase 2

Social Safety Learning in the Brain Oxytocin System

Key facts

Who runs it
University of Washington
Where
Seattle, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
121 people enrolled
Started
26 Jun 2023
Ended
30 Sept 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Oxytocin nasal spray or placebo
Record updated
11 June 2026

Who can take part

Age
18 years to 45 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • For Clinical Sample
  • Men and women age 18-45
  • Women must be having regular menstrual cycles and not be taking oral contraception
  • Primary diagnosis of social anxiety disorder; For Healthy Sample
  • Men and women age 18-45
  • Women must be having regular menstrual cycles and not be taking oral contraception
  • No current or lifetime history of psychiatric, neurological, or medical disorders

Who cannot take part

  • Positive urine drug screening test result
  • Current use of any psychotropic medication or steroids
  • History of nasal pathology
  • Active substance use disorder within the past 6 months
  • History of serious medical illnesses or untreated endocrine diseases
  • History of head injury, neurological disorder, or neurosurgical procedure
  • Lifetime diagnoses of mania or psychotic disorder based on the Diagnostic and Statistical Manual (DSM- 5th ed)
  • Lifetime DSM-5 diagnosis of any medical, neurological, or psychiatric illness
  • For All Groups
  • Pregnancy or breastfeeding
  • Positive magnetic resonance (MR) screen; For Clinical Sample
  • Acute suicidal ideation; For Healthy Sample

Where in United States

  • University of WashingtonSeattle, United States

About the trial

What the trial wants to find out

The investigators are conducting this research study to examine whether oxytocin enhances social safety learning (learning safety through the experience of another individual) in people with social anxiety disorder (SAD) compared to healthy volunteers. Oxytocin is a hormone that can also act as a chemical messenger in the brain. Oxytocin plays a role in a number of functions, including responding to fear and social interactions. In this study, the investigators would like to compare the effects of oxytocin and placebo nasal sprays in adults with SAD and healthy adults. This research study will compare an oxytocin nasal spray to a placebo nasal spray. About 120 people will take part in this research study, all at the University of Washington (UW).

The 2 groups in the trial

  • ClinicalTreatment being tested

    This group consists of individuals with at least moderate symptoms of social anxiety disorder. This group will receive either an oxytocin or placebo administration (blind randomization).

    Treatment: Oxytocin nasal spray or placebo

  • ControlsPlacebo, for comparison

    This group consists of a healthy sample of individuals (no lifetime diagnoses of mania or psychotic disorders). This group will receive either an oxytocin or placebo administration (blind randomization).

    Treatment: Oxytocin nasal spray or placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
11 June 2026